Status:
TERMINATED
HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer
Lead Sponsor:
Wuhan University
Conditions:
Peritoneal Metastases From Gastric Cancer
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The prognosis of patients with unresectable peritoneal metastases from gastric cancer is poor. These patients may obtain survival benefit from radical gastrectomy and cytoreductive surgery (CRS). The ...
Detailed Description
To determine the efficacy and safety of HIPEC and systemic chemotherapy combined with Apatinib in the conversion therapy of peritoneal metastases from gastric cancer, patients undergo HIPEC with Docet...
Eligibility Criteria
Inclusion
- Histological proved diagnosis of gastric cancer.
- Unresectable peritoneal metastases and primary tumor proved at surgery.
- No evidence of distant metastases.
- Have not received radiotherapy, chemotherapy or immunotherapy.
- ECOG score: 0\~2.
- Written informed consent is obtained prior to commencement of trial treatment.
Exclusion
- Existence of distant metastasis outside the abdomen.
- Any previous radiotherapy, chemotherapy or immunotherapy.
- Active systemic infections.
- Inadequate cardiac function, renal function, liver function or bone marrow function at the beginning of the trial.
- Female patients who are pregnant or breast feeding
Key Trial Info
Start Date :
January 5 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 20 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03349827
Start Date
January 5 2018
End Date
March 20 2020
Last Update
March 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wuhan University
Wuhan, Hubei, China